Jun 5, 2024
Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types.
Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility."
"When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials."
#Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech